

What is claimed is:

1. A method for the treatment of cancer, said method comprising administration of 4-desacetyl-4-methylcarbonate taxol and doxorubicin to a patient in need thereof.
2. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol and doxorubicin are administered sequentially.
3. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol and doxorubicin are administered simultaneously.
4. The method as claimed in claim 2, wherein said doxorubicin is administered initially followed by administration of 4-desacetyl-4-methylcarbonate taxol.
5. The method as claimed in claim 2, wherein said 4-desacetyl-4-methylcarbonate taxol is administered initially followed by administration of doxorubicin.
6. The method as claimed in claim 1, wherein said doxorubicin is administered in a dosage unit ranging between about 40-200 mg.
7. The method as claimed in claim 1, wherein said doxorubicin is administered in a dosage unit ranging between about 40-150 mg.
8. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol is administered in a dosage unit ranging from between about 50-380 mg.

9. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol is administered in a dosage unit ranging from between about 50-300 mg.

5 10. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol and doxorubicin are sequentially infused into a patient and the interval between infusions ranges between about 30 minutes to about 24 hours.

10 11. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol and doxorubicin are sequentially infused into a patient and the interval between infusions is about one hour.

15 12. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol and doxorubicin are administered via an administration means selected from the group consisting of intravenous administration,
20 intramuscular administration, intraperitoneal injection and oral administration.

25 13. The method as claimed in claim 1, wherein said 4-desacetyl-4-methylcarbonate taxol and doxorubicin are administered intravenously.

30 14. The method as claimed in claim 1, wherein said cancer is selected from the group consisting of breast cancer, ovarian cancer and lung cancer.

15. A chemotherapeutic combination composition comprising a chemotherapeutically effective amount of 4-desacetyl-4-methylcarbonate taxol and doxorubicin.

35 16. The chemotherapeutic combination composition of claim 15 in a pharmaceutically acceptable carrier.

17. The method for the chemotherapeutic treatment of cancer in a patient in need of such treatment, comprising administering to said patient the composition of claim 16.

5